Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Yusuke Mizukami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1068-7024; OpenAlex author ID A5017762006, A5025471308. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 25

  1. Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-026-02382-9↗
  2. Liquid Biopsy for Early Pancreatic Cancer Detection: Why Has It Not Yet Worked? Last author DOI 10.3390/cancers18030525↗
  3. Thiol methyltransferase METTL7B coordinates lipid metabolism and promotes tumor progression in pancreatic cancer Co-author DOI 10.64898/2026.04.09.717095↗
  4. Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic c… Co-author DOI 10.1002/1878-0261.70011↗
  5. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  6. Liquid Biopsy for Pancreatic Cancer by Serum Extracellular Vesicle-Encapsulated Long Noncoding RNA HEVEPA. Co-author DOI 10.1097/mpa.0000000000002315↗
  7. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  8. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. Co-author DOI 10.1007/s00535-021-01846-4↗
  9. [A case of incipient pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm, confirmed by multiregion sequencing analysis]. Last author DOI 10.11405/nisshoshi.119.368↗
  10. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  11. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-022-11735-6↗
  12. Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model. Co-author DOI 10.1016/j.pan.2021.03.002↗
  13. Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable … Co-author DOI 10.1136/bmjopen-2020-045698↗
  14. Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer. Co-author DOI 10.3389/fmolb.2021.717890↗
  15. Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative c… Co-author DOI 10.1097/md.0000000000020564↗
  16. Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis. First author DOI 10.3389/fonc.2020.00728↗
  17. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Co-author DOI 10.1053/j.gastro.2018.10.029↗
  18. Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. Co-author DOI 10.1055/a-1034-7700↗
  19. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Co-author DOI 10.1073/pnas.1901765116↗
  20. Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. Co-author DOI 10.1055/a-0721-1747↗
  21. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Last author DOI 10.1038/ctg.2017.3↗
  22. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
  23. Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). Last author DOI 10.1002/cjp2.8↗
  24. Macrophages in pancreatic cancer: starting things off on the wrong track. First author DOI 10.1083/jcb.201307066↗
  25. Bone marrow-derived proangiogenic cells in pancreatic cancer. Co-author DOI 10.1111/j.1440-1746.2011.07012.x↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Takahashi · 7 shared papers, 2021–2026 · strength 1.51
  2. Mikihiro Fujiya · 8 shared papers, 2019–2026 · strength 1.27
  3. Toshikatsu Okumura · 10 shared papers, 2018–2026 · strength 1.17
  4. Hidemasa Kawabata · 8 shared papers, 2018–2026 · strength 1.09
  5. Hiroki Sato · 7 shared papers, 2018–2025 · strength 0.87
  6. Tetsuhiro Okada · 7 shared papers, 2018–2026 · strength 0.77
  7. Yuko Omori · 7 shared papers, 2018–2025 · strength 0.73
  8. Toru Furukawa · 5 shared papers, 2019–2025 · strength 0.58
  9. Satoshi Hirano · 4 shared papers, 2019–2025 · strength 0.57
  10. Junpei Sasajima · 7 shared papers, 2015–2021 · strength 0.55
  11. Krushna Chandra Patra · 2 shared papers, 2017–2026 · strength 0.45
  12. Yohei Kitano · 2 shared papers, 2024–2026 · strength 0.39
  13. Kazuya Koyama · 2 shared papers, 2024–2026 · strength 0.39
  14. Andrew Scott Liss · 2 shared papers, 2022–2025 · strength 0.35
  15. Toru Nakamura · 2 shared papers, 2022 · strength 0.34
  16. Masato Ono · 2 shared papers, 2022 · strength 0.34
  17. Shinya Tanaka · 3 shared papers, 2019–2022 · strength 0.33
  18. Michiaki Unno · 2 shared papers, 2023–2025 · strength 0.31
  19. Atsushi Masamune · 2 shared papers, 2023–2025 · strength 0.31
  20. Kentaro Kawata · 1 shared paper, 2026 · strength 0.28
  21. Shuhei Mitsutomi · 1 shared paper, 2026 · strength 0.28
  22. Junko Tanaka · 1 shared paper, 2025 · strength 0.24
  23. Takahide Yokoi · 1 shared paper, 2025 · strength 0.24
  24. Nabeel M. Bardeesy · 3 shared papers, 2013–2017 · strength 0.22
  25. Masahiro Sato · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.